Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.1679
−$0.0021 · -1.24%
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Regular session
$0.1679
−$0.0021 · -1.24%
Regular session · ET · Market data may be delayed.
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Day range
Current $0.1679
52-week range
Current $0.1679
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
51
Mixed
Risk
63
High Risk
Momentum
35
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Day range
Current $0.1679
52-week range
Current $0.1679
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 7.72M USD | 3.53M USD | 193.58K USD | 646.38K USD | 1.18M USD |
| Selling, general, and administrative | 17.92M USD | 7.65M USD | 2.46M USD | 332.03K USD | 258.01K USD |
| Operating expenses | 18.35M USD | 11.18M USD | 4.73M USD | 978.42K USD | 1.44M USD |
| Interest income | — | 104.41K USD | 10.72K USD | −575.45K USD | −575.45K USD |
| Interest expense | 141.26K USD | 317.54K USD | 595.54K USD | 526.83K USD | 115.41K USD |
| Depreciation and amortization | — | — | 2.07M USD | — | — |
| Operating income | −18.35M USD | −11.18M USD | −4.73M USD | −978.42K USD | −1.44M USD |
| Net income | −25.37M USD | −11.16M USD | −5.31M USD | −1.69M USD | −2.06M USD |
Company facts updated Sep 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$1.00
495.59% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
